ConvaTec Group (LON:CTEC) Given Buy Rating at Stifel Nicolaus

ConvaTec Group (LON:CTEC)‘s stock had its “buy” rating reiterated by analysts at Stifel Nicolaus in a research note issued to investors on Wednesday,London Stock Exchange reports. They currently have a GBX 315 price objective on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 33.36% from the company’s previous close.

Several other research firms have also recently issued reports on CTEC. Citigroup reiterated an “outperform” rating and issued a GBX 315 target price on shares of ConvaTec Group in a research note on Thursday, March 5th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of ConvaTec Group in a report on Friday, November 14th. Peel Hunt reiterated an “add” rating and issued a GBX 270 price objective on shares of ConvaTec Group in a research report on Thursday, November 13th. Finally, Berenberg Bank lifted their price objective on ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, ConvaTec Group has a consensus rating of “Buy” and a consensus target price of GBX 319.

ConvaTec Group Price Performance

Shares of ConvaTec Group stock traded down GBX 6.60 on Wednesday, reaching GBX 236.20. The stock had a trading volume of 300,110,219 shares, compared to its average volume of 24,001,486. The business’s 50 day moving average is GBX 235.94 and its two-hundred day moving average is GBX 236.67. The company has a current ratio of 1.53, a quick ratio of 0.96 and a debt-to-equity ratio of 106.19. ConvaTec Group has a 1 year low of GBX 209.40 and a 1 year high of GBX 311.20. The company has a market cap of £4.60 billion, a P/E ratio of 27.47, a price-to-earnings-growth ratio of 0.93 and a beta of 0.76.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.